NCT05432401 - TAA05 Injection in the Treatment of Adult Patients With FLT3-positive Relapsed/Refractory Acute Myeloid Leukemia | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 9, 2022

Primary Completion Date

June 9, 2023

Study Completion Date

June 9, 2025

Conditions

FLT3-positive Relapsed/Refractory Acute Myeloid Leukemia

Interventions

BIOLOGICAL

T cell injection targeting FLT3 chimeric antigen receptor

The subjects, who sign the informed consent forms and been screened by inclusion/exclusion criteria, will be assigned into 1.0 × 10\^8, 2.0 × 10\^8 and 4.0 × 10\^8 CAR-T groups in order of sequence. And the subjects will be administered once.

Trial Locations (1)

430000

RECRUITING

Union Hospital, affiliated with TongJi Medical College, HuaZhong University of Science and Technology, Wuhan